Title: Single arm, open label, signal seeking, phase II trial of pamiparib in patients with relapsed/ refractory myeloid haematological malignancy with aberrant germline or somatic DNA repair pathway function.
The aim of this MoST-LLy substudy is to assess the clinical activity of pamiparib in patients with acute myeloid leukaemia (AML) or myelodysplastic syndrome (MDS) with germline or somatic DNA repair pathway mutation (e.g. BRCA1/2), and/or BRCA mutational signature.
Eligible Population: Adult patients with acute myeloid leukaemia or myelodysplastic syndrome who have no standard of care options or have failed these options and have enrolled in the MoST program and found to have germline or somatic DNA repair pathway mutation (e.g. BRCA1/2), and/or BRCA mutational signature.
Substudy status: recruiting
ANZCTR registration number: ACTRN12621001183875
ANZCTR registration details
